Trading Statement

Alliance Pharma PLC
10 March 2004

10 March 2004


                              ALLIANCE PHARMA PLC
                        ('Alliance' or 'the Company')

                            PRE-CLOSE TRADING UPDATE


Alliance Pharma plc, the emerging speciality pharmaceutical company, is pleased
to announce that trading has continued to be strong following its AIM flotation
on 27 November 2003.


Sales for the year ending 28 February 2004 are slightly ahead of management's
expectations set out at the time of the Company's flotation and are expected to
be in the region of £10.4 million, an increase of around 25% for the same period
in the previous financial year.


Preliminary results for the 12 month period to 28 February 2004 will be
announced on 12 May 2004.


John Dawson, CEO of Alliance Pharma, commented:


'These good results accompany the solid progress we have made in building the
company  in the few months since the flotation.  We have made the key
appointment of Michael Gatenby as non-executive Chairman and have acquired
Dermapharm Ltd which provides us with an extra four dermatology brands to add to
our existing portfolio and to complement the opportunities which will arise from
our distribution agreement with Barrier Therapeutics Inc.'


                                    - ends -


For further information:

Alliance Pharma plc
John Dawson, CEO
01249 466966


Beattie Financial
James Chandler/Mike Wort/John Moriarty
020 7398 3300


About Alliance Pharma


Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire.  The company has a strong
track record of acquiring the rights to established niche brands and owns, or
shares, the rights to 27 branded pharmaceutical products and is currently
exploring several opportunities to expand the range.  In November 2003 the
company acquired Peerless Technology Group Plc constituting a reverse takeover
under the AIM rules.


Alliance's products are prescribed in the treatment of a wide range of
conditions and include brands used in the prevention of heart disease, in
Parkinson's disease, in nasal infections, in the treatment of dermatological
conditions and in childbirth.  Alliance's sales are mainly prescription driven.
They are distributed to hospitals directly and to pharmaceutical wholesalers who
service both hospital and retail pharmacies with their prescription
requirements.




                      This information is provided by RNS
            The company news service from the London Stock Exchange